PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25609059-4 2015 RESULTS: We confirm that both trabectedin and doxorubicin were able to strongly reduce EWS-FLI1 (both type I and type II) binding to two representative target genes (TGFbetaR2 and CD99), both in vitro and in xenografts. Trabectedin 30-41 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 91-95 25809543-1 2015 PURPOSE: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. Trabectedin 122-133 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 242-246 25609059-5 2015 However, trabectedin, but not doxorubicin, was also able to increase the occupancy of EWS-FLI1 to IGF1R promoters, leading to IGF1R upregulation. Trabectedin 9-20 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 90-94 24277455-5 2014 Because WRN-deficient cells are known to be hypersensitive to camptothecins, we utilize trabectedin to block EWS-FLI1 activity, suppress WRN expression, and selectively sensitize Ewing sarcoma cells to the DNA-damaging effects of SN38. Trabectedin 88-99 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 113-117 21403840-4 2011 We demonstrate that, among a panel of pediatric sarcomas, Ewing sarcoma family of tumors (ESFTs) cell lines bearing the EWS-FLI1 transcription factor are the most sensitive to treatment with ET-743 compared with osteosarcoma, rhabdomyosarcoma, and synovial sarcoma. Trabectedin 191-197 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 124-128 21403840-5 2011 We show that ET-743 reverses a gene signature of induced downstream targets of EWS-FLI1 in two different ESFT cell lines (P = .001). Trabectedin 13-19 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 83-87 21403840-6 2011 In addition, ET-743 directly suppresses the promoter activity of a known EWS-FLI1 downstream target NR0B1 luciferase reporter construct without changing the activity of a constitutively active control in ESFT cells. Trabectedin 13-19 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 77-81 21403840-7 2011 Furthermore, the effect is specific to EWS-FLI1, as forced expression of EWS-FLI1 in a cell type that normally lacks this fusion protein, HT1080 cells, induces the same NR0B1 promoter, but this activation is completely blocked by ET-743 treatment. Trabectedin 230-236 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 43-47 21403840-7 2011 Furthermore, the effect is specific to EWS-FLI1, as forced expression of EWS-FLI1 in a cell type that normally lacks this fusion protein, HT1080 cells, induces the same NR0B1 promoter, but this activation is completely blocked by ET-743 treatment. Trabectedin 230-236 Fli-1 proto-oncogene, ETS transcription factor Homo sapiens 77-81